Research that is free to access for all investors. Companies commission these providers to write research about them.
Brokers who write research on their corporate clients and make it available through our main bundle offering.
Research that is paid for directly by asset managers. Only accessible to institutional investors permissioned for access.
Event in Progress:
Discover the latest content that has just been published on Research Tree
RELX released organic sales growth figures in line with expectations, confirming the strong momentum seen in H1 23. The guidance was reiterated despite the potential macro headwinds.
Companies: RELX PLC
AlphaValue
The markets are cheering the solid results reported by RELX in terms of revenue and profitability growth across all divisions as well as the announcement of an increase in its interim dividend. The guidance was reaffirmed for the year with the performance expected to be above the historical trend.
RELX’s results for FY22 came in above expectations. The continued growth in earnings as well as the EPS, dividend and share buyback program of £800m are being rewarded by investors who are boosting the share price to a new high.
This is our first report on Relx, a well-known provider of information-based analytics and decision tools for professionals as well as businesses. In the first half of 2022, the company generated solid financial results, with revenue growing by 13% at constant exchange rates. Business Services, accounting for around 45% of the division's sales, produced a significant revenue increase. Their digital identification solutions for fraud and identity saw extremely significant growth, with ThreatMetri
Baptista Research
The 9-months 2022 trading statement was in line, confirming organic revenue growth above historical trends for the second year. The group reiterated its FY22e guidance as “momentum remains strong”, which is very reassuring in light of the current macro environment.
RELX reported excellent H1 22 results in light of the current macro environment. The management said that the momentum remains strong entering H2 22 and that it continues to expect the FY22e performance to be above the historical trend.
RELX released a reassuring trading statement ahead of its April 2022 AGM to confirm its FY22e outlook, as all business lines performed well in Q1 22. Not to look a gift horse in the mouth, but perhaps a little more detail about Exhibitions would have been appreciated…
RELX’s FY21 top- and bottom-line trends fall short of expectations, dampening investor sentiment. The better-than-anticipated adjusted EPS and dividend, as well as the long-awaited return of the share buy-back programme, were not enough to support the share price…
RELX shares reached a new all-time high this morning following the publication of the group’s 9-month trading update. Investors welcomed the – long-awaited – bounce back in Exhibitions as well as the improved FY21e guidance.
RELX raised its FY21e guidance on the back of very encouraging H1 21 results. Its three major divisions delivered a sound performance, similar to pre-COVID-19 trends, which offset the continued weakness in Exhibitions.
RELX released a trading statement ahead of its April 2021 AGM to confirm its FY21e outlook as most of the business performed well in Q1 21. The timing and pace of recovery in Exhibitions remains uncertain.
The FY20 results are both satisfactory and in line. More than 4/5ths of the business are continuing to hold up well, with uncertainty remaining on Exhibitions. The FY dividend’s increase by 3% is good news. Positive stance maintained after allowing for negative tweaks on the Exhibitions outlook.
RELX issued a fairly sound 9 month trading statement despite the Exhibitions division remaining highly impacted by the current pandemic. More than 4/5 of the business are continuing to hold up well, which we consider a positive. The FY20e outlook is unchanged for the three largest divisions while Exhibitions continue to suffer. Some downgrade adjustments are expected to our forecasts, mostly due to Exhibitions, but we intend to reiterate a positive recommendation on the stock.
RELX’s H1 20 results are clearly not good, impacted by COVID-19 as expected. Both revenues and adjusted OP were below our estimates and the street’s as Exhibitions were significantly hurt. Positively, all other businesses continued to deliver and are continuing to hold up well. The flat interim dividend, contrary to market fears, was also a positive. Our earnings will be downgraded. High volatility expected going forward for the share price but we remain confident in the group’s long-term strate
RELX just released a trading statement ahead of is 23 April 2020 AGM to inform that it has suspended both its FY20e guidance and share buy-back due to the uncertainties related to COVID-19.
Research Tree provides access to ongoing research coverage, media content and regulatory news on RELX PLC. We currently have 0 research reports from 7 professional analysts.
Post further analysis of the FY 2023 results on 9 April 2024, we are establishing FY 2025 forecasts, as well as modifying our forecast adjusted net profit/EPS figures for 2024 and 2025 to reflect the accounting of the deferred tax asset. Our 2025 forecast calls for 9% growth in customer revenues, stable other operating income (largely R&D tax credits) vs 2024, EBITDA margins going back to the 23% level (after a slight contraction in 2024 to reflect 3 facilities being run in parallel for part of
Companies: hVIVO plc
Cavendish
The clinical diagnosis of Alzheimer’s Disease (AD) continues to be a highly challenging endeavour and existing gold standard diagnostic techniques (PET scans, CSF analysis) are limited by their cost, lack of access and perceived invasiveness. As the therapeutic landscape of AD evolves so too are the tools being developed to diagnose and monitor AD in clinical practice and blood-based AD tests represent potentially more sustainable, scalable and economically viable approaches to future AD managem
Companies: Bioventix Plc
Elixirr offers investors exposure to the long-term growth trends in the global Consulting market (including digitisation and the ongoing technology revolution, demand for innovation, efficiency and specialised expertise) all turbo charged by the group’s ‘challenger’ strategy driving market share gain from a low base. FY 2023 results showed the power of Elixirr’s differentiated model with revenue up +20% and adj. EPS up +22% in a market subdued by global uncertainty. With net cash of £18m, a posi
Companies: Elixirr International Plc
Companies: FOG PHC FEN BBSN ELIX
CLIG’s 3Q IMS reveals 5.5% rise in FuM in the first three months to March 2024 to US$10.1 billion. In the quarter performance added US$302m and group net inflows were US$224m.
Companies: City of London Investment Group PLC
Zeus Capital
Companies: MPE TRI VNET BVXP HVO
The focus of Hardman & Co Research is on the nine quoted Infrastructure Investment Companies (IICs) and on the 22 Renewable Energy Infrastructure Funds (REIFs): the stocks analysed are all members of the Association of Investment Companies (AIC). We are updating our publication of January 2023, assessing both the lacklustre share price performances during 2023 and the key issues, including interest rates, inflation and power prices. As a 31-strong group, its combined market capitalisation is no
Companies: AEIT ROOF DGI9 INPP GSF SEIT USFP HICL ORIT BSIF TRIG NESF SEQI HEIT GRP GCP FSFL 3IN AERI PINT RNEW BBGI GSEO DORE TENT GRID CORD HGEN AEET
Hardman & Co
Companies: Merit Group PLC
Canaccord Genuity
Companies: Science Group Plc
Liberum
Companies: AURA OMI AAL KAV POW BMN EST SVML
SP Angel
Companies: Mind Gym Plc
hVIVO has delivered FY 2023A results in-line with the 30 January 2024 TU, with total customer revenues of £56m, growth of 16% versus 2022A. Other income related to tax credits added another £2.6m. 2024 revenue guidance of £62m has been reiterated, representing 11% growth over 2023A, and ahead of the £60m that we had previously forecast. The company has good visibility with the 2024 figure, with 90% already being covered by the existing orderbook (stands at £80m at the end of 2023), as well as in
A positive trading trajectory for MLVN has continued to emerge strongly in this morning's results, with FY23A revenues standing at £12.2m (FY22A: £6.3m / +79%) and £0.2m PBT profit as against a £1.1m PBT loss the year before (excluding a £94k fair value movement / loan write back). MLVN provides education services including (1) a range of university-related courses for overseas students, (2) adult ELT and (3) summer schools for juniors. MLVN's contract with the University of East London (UEL) st
Companies: Malvern International plc
WHIreland
Companies: JDW MAB MARS WTB FSTA BOWL CPG SSPG LGRS SSTY OTB HSW TMO GYM MEX
25th April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: Smart Metering Systems (SMS.L) has delisted from the AIM market What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: 16 April 2024: Electric Guitar (ELEG.L) Concurrent with its Admission to trading on AIM, Electric Guitar
Companies: SKL CAM HRN VNET NBB DEST ZIN CRCL
Hybridan
Share: